GEN Exclusives

More »

GEN News Highlights

More »
Oct 1, 2007

Novelos and Univ. of South Carolina Win STTR Grant to Advance Phase III Oncology Trial

  • Novelos Therapeutics and the Medical University of South Carolina (MUSC) were awarded a $150,000 phase 1 STTR grant by the NIH. The funding will support further development of NOV-002, the company’s lead candidate, which is in a pivotal Phase III trial for non-small-cell lung cancer. 

    “NOV-002 is a novel drug capable of modifying redox-based cell processes and represents a valuable tool for linking such processes to clinical endpoints in oncology patients,” explains Kenneth D. Tew, Ph.D., principal investigator on the grant. Dr. Tew also is chairman of the company’s scientific advisory board and chair of the MUSC Department of Cell and Molecular Pharmacology & Experimental Therapeutics.

    “The research supported by this initial STTR grant will focus on continued identification of the molecular targets of NOV-002 and the therapy-relevant consequences of their modulation,” Dr. Tew continues.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?